FDA Approves Fayuvi for MPS IIIA
FDA approved Fayuvi, a one-time intravenous AAV9 gene therapy, for neurologic manifestations of mucopolysaccharidosis IIIA in pediatric patients with preserved neurodevelopmental function. The approval is the first U.S. treatment for Sanfilippo syndrome type A….
